JP2018500322A - ワクチン接種 - Google Patents

ワクチン接種 Download PDF

Info

Publication number
JP2018500322A
JP2018500322A JP2017532039A JP2017532039A JP2018500322A JP 2018500322 A JP2018500322 A JP 2018500322A JP 2017532039 A JP2017532039 A JP 2017532039A JP 2017532039 A JP2017532039 A JP 2017532039A JP 2018500322 A JP2018500322 A JP 2018500322A
Authority
JP
Japan
Prior art keywords
composition
vaccine
immunogenic composition
years
vaccine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500322A5 (OSRAM
Inventor
ハイネマン，トーマス，チャールズ
レデント，エドワール，ガイ，クリスチャン
レクレニエール，ニコラス，ピエール，フェルナンド
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201503266A external-priority patent/GB201503266D0/en
Priority claimed from GBGB1518917.8A external-priority patent/GB201518917D0/en
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2018500322A publication Critical patent/JP2018500322A/ja
Publication of JP2018500322A5 publication Critical patent/JP2018500322A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2017532039A 2014-12-18 2015-12-16 ワクチン接種 Pending JP2018500322A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1422686.4 2014-12-18
GB201422686 2014-12-18
GB1503266.7 2015-02-26
GB201503266A GB201503266D0 (en) 2015-02-26 2015-02-26 Vaccination
GB1518917.8 2015-10-26
GBGB1518917.8A GB201518917D0 (en) 2015-10-26 2015-10-26 Vaccination
PCT/EP2015/079967 WO2016096968A1 (en) 2014-12-18 2015-12-16 Vaccination

Publications (2)

Publication Number Publication Date
JP2018500322A true JP2018500322A (ja) 2018-01-11
JP2018500322A5 JP2018500322A5 (OSRAM) 2018-12-27

Family

ID=54937057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017532039A Pending JP2018500322A (ja) 2014-12-18 2015-12-16 ワクチン接種

Country Status (8)

Country Link
US (1) US20180008700A1 (OSRAM)
EP (1) EP3233118A1 (OSRAM)
JP (1) JP2018500322A (OSRAM)
CN (1) CN107106675A (OSRAM)
BR (1) BR112017012647A2 (OSRAM)
CA (1) CA2970840A1 (OSRAM)
MX (1) MX2017008055A (OSRAM)
WO (1) WO2016096968A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201891001A1 (ru) * 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
AU2016349693B2 (en) 2015-11-06 2022-08-11 Adjuvance Technologies, Inc. Triterpene saponin analogues
WO2018198085A1 (en) 2017-04-28 2018-11-01 Glaxosmithkline Biologicals Sa Vaccination
JP7247226B2 (ja) * 2018-05-23 2023-03-28 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 水痘・帯状疱疹ウイルスの抗原バリアントおよびその使用
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CN114630671A (zh) * 2019-11-05 2022-06-14 佐剂技术公司 水痘带状疱疹
WO2023223255A1 (en) * 2022-05-20 2023-11-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531637A (ja) * 2005-03-03 2008-08-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 水疱−帯状疱疹ウイルスワクチン

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531637A (ja) * 2005-03-03 2008-08-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 水疱−帯状疱疹ウイルスワクチン

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BERKOWITZ, ELCHONON M. ET AL., JOURNAL OF INFECTIOUS DISEASES, vol. 211, no. 8, JPN6019035693, 3 November 2014 (2014-11-03), pages 1279 - 1287, ISSN: 0004115900 *
CHLIBEK ROMAN: "Safety and Immunogenicity Of Three Different Formulations Of An Adjuvanted Varicella-Zoster Virus Su", VACCINE, vol. VOL:32, NR:15,, JPN5017010644, 6 February 2014 (2014-02-06), pages 1745 - 1753, ISSN: 0004115896 *
CHLIBEK, ROMAN ET AL., JOURNAL OF INFECTIOUS DISEASES, vol. 208, no. 12, JPN6019035691, 15 December 2013 (2013-12-15), pages 1953 - 1961, ISSN: 0004115897 *
LEROUX-ROELS, ISABEL ET AL., JOURNAL OF INFECTIOUS DISEASES, vol. 206, no. 8, JPN6019035692, October 2012 (2012-10-01), pages 1280 - 1290, ISSN: 0004115898 *
MORRISON, VICKI A. ET AL., CLINICAL INFECTIOUS DISEASE, vol. 60, no. 20, JPN6019035690, 20 November 2014 (2014-11-20), pages 900 - 909, ISSN: 0004251812 *
OXMAN M N: "A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia In Older Adults", NEW ENGLAND JOURNAL OF MEDICINE, vol. VOL:352, NR:22,, JPN5017010648, 2 June 2005 (2005-06-02), pages 2271 - 2284, ISSN: 0004115899 *
STADTMAUER, EDWARD A. ET AL., BLOOD, vol. 124, no. 19, JPN6019035694, 6 November 2014 (2014-11-06), pages 2921 - 2929, ISSN: 0004115901 *

Also Published As

Publication number Publication date
CA2970840A1 (en) 2016-06-23
MX2017008055A (es) 2017-09-28
EP3233118A1 (en) 2017-10-25
CN107106675A (zh) 2017-08-29
WO2016096968A1 (en) 2016-06-23
BR112017012647A2 (pt) 2018-01-09
US20180008700A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
JP2018500322A (ja) ワクチン接種
Heineman et al. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine
CA2797937C (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP2012527486A5 (OSRAM)
US11951161B2 (en) Methods for inducing an immune response
US20210187098A1 (en) Vaccination
JP2018500322A5 (OSRAM)
EP1109574B1 (en) Vaccine against sexually transmitted diseases
Esposito et al. Herpes zoster prevention: a difficult problem to solve
Levin et al. Adjuvanted recombinant glycoprotein E herpes zoster vaccine
CA3157372A1 (en) Varicella zoster
BE1022523B1 (fr) Vaccination
WO2016046113A1 (en) Novel methods for inducing an immune response
Cunningham et al. Herpes Zoster Vaccines: What's New?
Kuipers et al. The immunogenicity of recombinant zoster vaccination in patients with secondary immunodeficiencies: a literature review
WO2023183136A1 (en) Composition comprising antigen and dna and use thereof
HEINEMAN Herpes Zoster Vaccines: What’s New?
Aerssens et al. Adjuvanted herpes zoster subunit vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200414